Hyperkalemia Market is Projected to Grow During the Forecast Period (2022-2032) – Estimates DelveInsight | Key Companies – Ardelyx, Zeria Pharmaceutical, AstraZeneca, Vifor Pharma

 Breaking News
  • No posts were found

Hyperkalemia Market is Projected to Grow During the Forecast Period (2022-2032) – Estimates DelveInsight | Key Companies – Ardelyx, Zeria Pharmaceutical, AstraZeneca, Vifor Pharma

June 05
07:16 2023
Hyperkalemia Market is Projected to Grow During the Forecast Period (2022-2032) - Estimates DelveInsight | Key Companies - Ardelyx,  Zeria Pharmaceutical, AstraZeneca, Vifor Pharma
Delveinsight Business Research LLP
The Hyperkalemia market size in the seven major markets was approximately USD 1,198 million in 2021, which is further expected to increase by 2032. The Hyperkalemia Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Hyperkalemia patients in the 7MM and the launch of new therapies in the market.

DelveInsight’s “Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hyperkalemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hyperkalemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hyperkalemia: An Overview

According to the National Kidney Foundation, hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.

The risk factors for hyperkalemia include several factors such as chronic kidney disease, diabetes, congestive heart failure, and certain medications that disrupt the potassium balance. Common acute manifestations of significant hyperkalemia include muscle weakness and ECG changes, with the latter having the potential to progress to a life-threatening arrhythmia.

Hyperkalemia Market Key Facts

  • The market size in the 7MM will increase at a CAGR of 5.7% due to the increasing prevalence of the disease.

  • Among the 7MM countries, the US accounted for the highest market size of Hyperkalemia with USD 970 million in 2021 which is likely to increase by 2032.

  • Among EU4 and the United Kingdom, Germany accounted for USD 49 million in 2021, followed by the United Kingdom with USD 38 million in the same year, while Spain accounted for the lowest market with USD 4 million in 2021.

  • Japan accounted for USD 127 million in 2021, which is expected to increase by 2032.

  • In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,046 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019–2032).

  • Among the 7MM, the United States accounted for nearly 79% of the total diagnosed prevalent cases of Hyperkalemia in the 7MM in the year 2021 which is expected to increase further by 2032.

  • Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.

Hyperkalemia Market

Hyperkalemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hyperkalemia pipeline therapies. It also thoroughly assesses the Hyperkalemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Hyperkalemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hyperkalemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hyperkalemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hyperkalemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hyperkalemia Epidemiology, Segmented as –

  • Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019–2032]

  • Prevalent Cases of Hyperkalemia by Severity in the 7MM [2019–2032]

  • Gender-specific Prevalence of Hyperkalemia in the 7MM [2019–2032]

  • Age-Specific Diagnosed Prevalence of Hyperkalemia in the 7MM [2019– 2032]

  • Co-morbidity-specific Diagnosed Prevalent Cases of Hyperkalemia in the 7MM [2019– 2032]

Hyperkalemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperkalemia market or expected to be launched during the study period. The analysis covers the Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hyperkalemia drugs based on their sale and market share.

The report also covers the Hyperkalemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hyperkalemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hyperkalemia Market Will Evolve and Grow by 2032 @ 


Hyperkalemia Therapeutics Analysis

Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Hyperkalemia. There are several promising drugs in the pipeline including RDX013 (Ardelyx) Sodium Zirconium Cyclosilicate (AstraZeneca) among others.

Hyperkalemia Companies Actively Working in the Therapeutics Market Include

  • Ardelyx

  •  Zeria Pharmaceutical

  • AstraZeneca

  • Vifor Pharma

And Many Others

Emerging and Marketed Hyperkalemia Therapies Covered in the Report Include:

  • RDX013: Ardelyx

  • Sodium Zirconium Cyclosilicate (SZC)- AstraZeneca

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hyperkalemia Competitive Intelligence Analysis

4. Hyperkalemia Market Overview at a Glance

5. Hyperkalemia Disease Background and Overview

6. Hyperkalemia Patient Journey

7. Hyperkalemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperkalemia Unmet Needs

10. Key Endpoints of Hyperkalemia Treatment

11. Hyperkalemia Marketed Therapies

12. Hyperkalemia Emerging Drugs and Latest Therapeutic Advances

13. Hyperkalemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperkalemia Market Outlook (In US, EU5, and Japan)

16. Hyperkalemia Companies Active in the Market

17. Hyperkalemia Access and Reimbursement Overview

18. KOL Views on the Hyperkalemia Market

19. Hyperkalemia Market Drivers

20. Hyperkalemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Radiofrequency Ablation Devices Market

The Global Radiofrequency Ablation Devices Market was valued at USD 3.64 billion in 2021, growing at a CAGR of 9.37% during the forecast period from 2023 to 2028; it is expected to reach USD 6.19 billion by 2028. The demand for radiofrequency ablation devices is witnessing growth due to the growing prevalence of chronic diseases such as cardiovascular diseases, cancers, the rising geriatric population, and technological advancements in product development and design improvement.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles